Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;30(11-12):1561-1565.
doi: 10.1177/13524585241260977. Epub 2024 Jun 14.

Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres

Gloria Dalla Costa  1 , Letizia Leocani  1 , Marco Pisa  1 , Tommaso Croese  2 , Vittorio Martinelli  3 , Lucia Moiola  3 , Francesca Sangalli  3 , Bruno Colombo  3 , Aiden Haghikia  4 , Ralf Gold  4 , Roberto Furlan  2 , Giancarlo Comi  5
Affiliations

Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres

Gloria Dalla Costa et al. Mult Scler. 2024 Oct.

Abstract

Background: While John Cunningham virus (JCV) is known to cause neuronal damage in progressive multifocal leukoencephalopathy (PML) among natalizumab-treated MS patients, its association with axonal loss in non-PML conditions remains unclear.

Methods: In a cohort of 128 natalizumab-treated MS patients, serum neurofilament (sNfL) levels and JCV antibody titres were measured.

Results: Among 128 patients (mean age = 38.4 years, 71.9% female), 51 (40%) were JCV positive. NfL levels increased by 15.3% for JCV index <0.7 (95% confidence interval [CI] = 0.963-1.381), by 18.6% for index 0.7-1.5 (95% CI = 1.009-1.394) and by 21.1% for index >1.5 (95% CI = 1.040-1.409) compared to JCV negative patients.

Conclusion: These findings indicate a potential link between JCV burden and neuroaxonal degeneration in natalizumab-treated MS patients.

Keywords: JCV; Multiple sclerosis; natalizumab; neuroaxonal loss; neurofilaments.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: G.D.C., M.P., T.C., F.S., B.C., A.H., and R.G. report no disclosures. VM has received honoraria for activities with Biogen, Merck, Bayer, TEVA and Sanofi-Genzyme as a speaker. L.M. has received honoraria for speaking in scientific meetings and for advisory board from Biogen TEVA, Sanofi-Genzyme, and Merck. R.F. has received honoraria for speaker activities from Biogen, Merck, Novartis, Roche and Teva. L.L. has received honoraria for consulting services and/or speaking activity from Biogen, Novartis and Excemed. G.C. has received personal compensation for consulting services and/or speaking activities from Novartis, Teva, Sanofi, Sanofi-Genzyme, Merck, Biogen, Excemed, Serono Symposia International Foundation, Roche, Almirall, Receptos, Celgene and Forward Pharma.

LinkOut - more resources